Drug intelligence / Profile preview

camicinal

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Camicinal is a small molecule, investigational drug developed as an oral, selective motilin receptor agonist. It is designed to stimulate gastrointestinal motility by activating the motilin receptor, which enhances cholinergic contractility in the gastric antrum and accelerates gastric emptying. Camicinal has been primarily studied for the treatment of gastroparesis, including diabetic gastroparesis and gastroparesis associated with Parkinson’s disease. Clinical trials have shown that camicinal can improve gastric emptying and reduce symptoms without significant adverse effects or tachyphylaxis. The drug was originally developed by GlaxoSmithKline (now GSK) and reached up to phase II/III clinical trials before discontinuation in some regions[1][2][3][4][5][6][7].

Other names: camicinal

Targets

MLNR (Human motilin receptor)

Beyond the preview

Go deeper on camicinal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camicinal.

Explore the full profile